CA2201519A1 - Preparations de complexes peptide/systeme majeur d'histocompatibilite - Google Patents
Preparations de complexes peptide/systeme majeur d'histocompatibiliteInfo
- Publication number
- CA2201519A1 CA2201519A1 CA002201519A CA2201519A CA2201519A1 CA 2201519 A1 CA2201519 A1 CA 2201519A1 CA 002201519 A CA002201519 A CA 002201519A CA 2201519 A CA2201519 A CA 2201519A CA 2201519 A1 CA2201519 A1 CA 2201519A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- mbp
- mhc
- complexes
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des procédés pour préparer des complexes peptide/système majeur d'histocompatibilité ayant une composition définie. Le peptides sont utilisés en fort excès molaire. On peut également optimiser le pH de préparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31553994A | 1994-09-30 | 1994-09-30 | |
US08/315,539 | 1994-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2201519A1 true CA2201519A1 (fr) | 1996-04-11 |
Family
ID=23224886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002201519A Abandoned CA2201519A1 (fr) | 1994-09-30 | 1995-09-29 | Preparations de complexes peptide/systeme majeur d'histocompatibilite |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0792157A4 (fr) |
JP (1) | JPH10509693A (fr) |
KR (1) | KR970706014A (fr) |
AU (1) | AU3887495A (fr) |
CA (1) | CA2201519A1 (fr) |
WO (1) | WO1996010415A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824315A (en) * | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
JPH10509693A (ja) * | 1994-09-30 | 1998-09-22 | アナージェン, インコーポレイテッド | Mhc−ペプチド複合体の調製法 |
EP1379644A2 (fr) * | 2001-04-05 | 2004-01-14 | Nextgen Sciences Ltd | Analyse de proteines au moyen d'antigenes ou anticorps immobilises en reseaux |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130297A (en) * | 1988-06-23 | 1992-07-14 | Anergen, Inc. | Conjugates useful in ameliorating autoimmunity MHC-II-peptide |
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
ES2318848T3 (es) * | 1993-09-14 | 2009-05-01 | Pharmexa Inc. | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. |
JPH10509693A (ja) * | 1994-09-30 | 1998-09-22 | アナージェン, インコーポレイテッド | Mhc−ペプチド複合体の調製法 |
-
1995
- 1995-09-29 JP JP8512077A patent/JPH10509693A/ja not_active Ceased
- 1995-09-29 KR KR1019970702077A patent/KR970706014A/ko active IP Right Grant
- 1995-09-29 WO PCT/US1995/012575 patent/WO1996010415A1/fr not_active Application Discontinuation
- 1995-09-29 CA CA002201519A patent/CA2201519A1/fr not_active Abandoned
- 1995-09-29 EP EP95938126A patent/EP0792157A4/fr not_active Withdrawn
- 1995-09-29 AU AU38874/95A patent/AU3887495A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0792157A4 (fr) | 1999-12-01 |
KR970706014A (ko) | 1997-11-03 |
WO1996010415A1 (fr) | 1996-04-11 |
JPH10509693A (ja) | 1998-09-22 |
EP0792157A1 (fr) | 1997-09-03 |
AU3887495A (en) | 1996-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5763585A (en) | Method of making MHC-peptide complexes using metal chelate affinity chromatography | |
US6106840A (en) | MHC conjugates useful in ameliorating autoimmunity | |
JP3487849B2 (ja) | 自己免疫性を改善せしめるうえで有用なmhcコンジュゲート | |
US5468481A (en) | MHC class II-peptide conjugates useful in ameliorating autoimmunity | |
US5284935A (en) | MHC-mediated toxic conjugates useful in ameliorating autoimmunity | |
US5734023A (en) | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses | |
US5824315A (en) | Binding affinity of antigenic peptides for MHC molecules | |
CA1340012C (fr) | Determinant peptidique associe a l'immunite | |
JP3755894B2 (ja) | 自己免疫疾患の免疫療法に用いるための、自己抗原から誘導された新規なペプチド | |
EP0661985B1 (fr) | Peptides capables de se lier aux molecules cd8 sur les precurseurs de ctl | |
AU2013207489A1 (en) | Partial MHC constructs and methods of use | |
JPH11507914A (ja) | Mhc−ペプチド複合体の安定な処方物 | |
AU670024B2 (en) | Methods of treating or preventing autoimmune uveoretinitis in mammals | |
WO2003072598A2 (fr) | Peptides derives de hsp70 et utilisations de ceux-ci dans le diagnostic et le traitement de maladies auto-immunes | |
EP0630255B1 (fr) | Conjugues cmh permettant de traiter l'auto-immunite | |
WO1993009810A1 (fr) | Conjugues d'une subunite du complexe majeur d'histocompatibilite utiles pour ameliorer les reponses immunitaires deleteres | |
CA2223714A1 (fr) | Vaccination par peptides de molecules du cmh de classe ii destinee au traitement de maladie auto-immune | |
CA2201519A1 (fr) | Preparations de complexes peptide/systeme majeur d'histocompatibilite | |
WO1996010415A9 (fr) | Preparations de complexes peptide/systeme majeur d'histocompatibilite | |
EP0544862B1 (fr) | Méthodes et compositions pour la prophylaxie, le diagnostic et le traitement des inflammations séreuses et des troubles associés | |
US20230414732A1 (en) | Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use | |
JP2002521387A (ja) | 共重合体1および関連する共重合体ならびにペプチドによる自己免疫疾患の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |